Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

omputing Non-GAAP

adjusted diluted net income per share

79,14785,026GAAP diluted net income (loss)  per share

$
(0.98)$
.26Non-GAAP adjusted diluted net income 

per share

$
.15$
.37 

Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income (loss):

  1. Non-cash interest expense: Non-GAAP adjusted net income excludes non-cash interest expense on our convertible notes.  We believe that excluding the non-cash portion of our interest expense allows management and investors an alternative view of our financial results "as if" our net income reflected only the cash portion of our interest expense. 
  2. Purchase accounting and product acquisition related adjustments:  Non-GAAP adjusted net income excludes certain items related to our acquisitions. The excluded items may include among other adjustments; charges related to amortization of intangible assets arising from acquisitions and changes in the fair value of future contingent consideration or significant transaction costs.
  3. Share-based compensation expense: Non-GAAP adjusted net income excludes the impact of our non-cash share-based compensation expense. We believe that excluding the impact of expensing share-based compensation better reflects the recurring economic characteristics of our business.

Non-GAAP net income may exclude unusual or non-recurring items that are evaluated on an individual basis. Our evaluation of whether to exclude an item for purposes of determining our non-GAAP financial measures considers both the quantitative and qualitative aspects of the item, including, among other things (i) its size and nature, (ii) whether or not it relates to our ongoing business operations, and (iii) whether or not we expect it to occur as part of our normal business on a regular basis. For purposes of determining non-GA
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Participate in Two December Healthcare Investor Conferences
2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
8. WuXi PharmaTech Announces Third-Quarter 2011 Results
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Spherix Announces Third Quarter Financial Results
11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... ... of FireflySci Inc. (FFS) in early 2015, the company continues to shake up the cuvette ... in a lab coat and Large Marge have been posted on the company’s Facebook page ... is proud to be the only cuvette manufacturer is the world that has an online ...
(Date:8/27/2015)... 2015 The National Necrotizing Fasciitis Foundation ... saved by doctors at Vanderbilt University Hospital in ... Pharmaceuticals and Dr. John Crew , director of ... Medical Center in Daly City, CA. ... approach, pioneered by Dr. Crew, that had previously saved ...
(Date:8/27/2015)... ... August 27, 2015 , ... Inc. Magazine released its ... iLab Solutions as number 1,361 in growth for the three years through 2014. Being ... 0.1% fastest-growing privately held organizations in the country. , “We are thrilled to ...
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... an explanation as to where and how North Sea oil ... be the first step on the way to developing improved ... from Danish oil fields. , A research group at the ... of Copenhagen has investigated drill cores collected from North Sea ...
... Apex Bioventures Acquisition Corporation (NYSE Amex: PEX ... notice from NYSE Amex LLC (the "Exchange") that the ... accepted by the Exchange and the Company has been ... compliance with the continued listing standards of the Exchange.As ...
... China, May 11 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ... CSKI ), a leading,fully integrated pharmaceutical company producing ... announced that it will conduct a,conference call at 10:00 ... to discuss its first quarter of fiscal year 2009 ...
Cached Biology Technology:New Danish research shows how oil gets stuck underground 2Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 2China Sky One Medical, Inc. Schedules Conference Call to Discuss First Quarter 2009 Results 3
(Date:8/5/2015)... Calif. , Aug. 5, 2015 The ... continuous growth in applications, penetration into newer sectors, and ... year. The global biosensors space has seen the entry ... the market so far. (Photo - ... & Sullivan, Analysis of the Global Biosensors Market ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... , 31 de julio de 2015 La 10 ... se celebrará por medio de BGI del 22 al 25 de ... Este año, la conferencia celebra su décimo ... ha convertido en una de las reuniones anuales más influyentes ... de las reuniones más dinámicas, entusiastas y mejores a nivel ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... New Rochelle, NY, December 2, 2010 For ... addressed at the highest level of government. With the ... the U.S. Department of Health and Human Services has ... - and supporting breastfeeding is prominent among them. ...
... scientists at the University of Leicester have recorded stunning ... European Space Agency satellite instruments have been observing ... points in space. Leicester scientists have used ... images of a snow-bound UK from observations on November ...
... of Chicago Medical Center is designed to offer surgeons ... new molecular and mechanical solutions to three age-old problems: ... between blood vessels), improving tissue healing after surgery and ... The conference, "Solving the most challenging surgical ...
Cached Biology News:New public health goals tackle obstacles to breastfeeding success 2Snow from space: University of Leicester releases satellite images of snow-bound UK 2Conference goals include better surgery and better surgeons 2Conference goals include better surgery and better surgeons 3
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
TXNL2 Antibody...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Request Info...
Biology Products: